Literature DB >> 2828556

Multiple sclerosis and human T-cell lymphotropic retroviruses: negative serological results in 135 German patients.

J Schneider1, B Kitze, G Hunsmann, I Wendler, L Kappos.   

Abstract

A total of 135 sera and 18 cerebrospinal fluid (CSF) samples from patients with multiple sclerosis (MS) were screened for antibodies to human T-cell lymphotropic virus type I (HTLV-I) and human immunodeficiency virus (HIV) by ELISA tests. None of the sera or CSF reacted with HIV antigens. Only 3 out of 135 MS sera but no MS CSF showed increased reactions in the ELISA test for HTLV-I. However, these positive reactions were classified as non-specific by immunoprecipitation. Thus no serological evidence for infection with HIV, HTLV-I, or a related retrovirus was found in the MS patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828556     DOI: 10.1007/BF00718019

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  Lack of antibody to HTLV-I and HIV in patients with multiple sclerosis from France and French West Indies.

Authors:  A Gessain; L Abel; G De-The; J C Vernant; P Raverdy; A Guillard
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-16

2.  Search for HTLV-I and LAV/HTLV-III antibodies in serum and CSF of multiple sclerosis patients.

Authors:  A De Rossi; P Gallo; B Tavolato; L Callegaro; L Chieco-Bianchi
Journal:  Acta Neurol Scand       Date:  1986-08       Impact factor: 3.209

3.  Sera from patients with multiple sclerosis react with human cell T lymphotropic virus-I gag proteins but not env proteins--Western blotting analysis.

Authors:  M Ohta; K Ohta; F Mori; H Nishitani; T Saida
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

4.  HTLV-III infection in brains of children and adults with AIDS encephalopathy.

Authors:  G M Shaw; M E Harper; B H Hahn; L G Epstein; D C Gajdusek; R W Price; B A Navia; C K Petito; C J O'Hara; J E Groopman
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

5.  Analysis of human T-lymphotrophic virus sequences in multiple sclerosis tissue.

Authors:  S L Hauser; C Aubert; J S Burks; C Kerr; O Lyon-Caen; G de The; M Brahic
Journal:  Nature       Date:  1986 Jul 10-16       Impact factor: 49.962

6.  Lack of evidence for involvement of known human retroviruses in multiple sclerosis.

Authors:  A Karpas; U Kämpf; A Sidèn; M Koch; S Poser
Journal:  Nature       Date:  1986 Jul 10-16       Impact factor: 49.962

7.  Sera from adult T-cell leukemia patients react with envelope and core polypeptides of adult T-cell leukemia virus.

Authors:  J Schneider; N Yamamoto; Y Hinuma; G Hunsmann
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

8.  Detection of serum antibodies to adult T-cell leukemia virus in non-human primates and in people from Africa.

Authors:  G Hunsmann; J Schneider; J Schmitt; N Yamamoto
Journal:  Int J Cancer       Date:  1983-09-15       Impact factor: 7.396

9.  Multiple sclerosis and human T-cell lymphotropic retroviruses.

Authors:  H Koprowski; E C DeFreitas; M E Harper; M Sandberg-Wollheim; W A Sheremata; M Robert-Guroff; C W Saxinger; M B Feinberg; F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

10.  Absence of antibody to HTLV I and III in sera of Canadian patients with multiple sclerosis and chronic myelopathy.

Authors:  G P Rice; H A Armstrong; D E Bulman; D W Paty; G C Ebers
Journal:  Ann Neurol       Date:  1986-10       Impact factor: 10.422

View more
  2 in total

1.  Differential diagnosis of HTLV-I-associated myelopathy and multiple sclerosis in Iranian patients.

Authors:  B Kitze; R W Turner; M Burchhardt; S Poser; G Hunsmann; T Weber
Journal:  Clin Investig       Date:  1992-11

2.  A soluble form of tumour necrosis factor receptor in cerebrospinal fluid and serum of HTLV-I-associated myelopathy and other neurological diseases.

Authors:  M Puccioni-Sohler; P Rieckmann; B Kitze; P Lange; M Albrecht; K Felgenhauer
Journal:  J Neurol       Date:  1995-03       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.